South Korea allows phase II human trial for Green Cross's COVID treatment drug


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ south-korea-allows-direct-phase-2-human-trial-covid-drug
South Korea, desperate for Covid drug skips phase 1 trial

South Korea's Green Cross Corp (006280.KS) has received regulatory approval for phase II human clinical trials of its experimental coronavirus plasma treatment drug, the Ministry of Food and Drug Safety said on Thursday.

The trials will test the safety and efficacy of the drug in 60 severe patients with underlying conditions like pneumonia, Green Cross said.

Green Cross was allowed to skip phase I trials. Its therapy is the country's first to enter phase II for COVID-19 plasma treatment.

South Korea has reported its highest daily rise in coronavirus cases since early March as clusters of cases from churches around the capital Seoul have prompted new restrictions amid concerns of a nationwide wave of infections.

The 297 new infections reported on Wednesday mark the sixth straight day of triple-digit increase in a country that has managed to blunt several previous outbreaks.

The national tally rose to 16,058 infections with 306 deaths, according to data from the Korea Centers for Disease Control and Prevention.

"We're in a desperately dangerous crisis where infections are spreading in the Seoul metropolitan area and threatening to lead to a massive nationwide transmission," Vice Minister of Health Kim Gang-lip told a briefing.

"The government cannot contain the current spread only with tracing and isolation ... please stay home unless you need to go out."

Officials have also enforced stronger physical distancing restrictions for Seoul, Incheon and nearby Gyeonggi province that prohibit gatherings of more than 50 people indoors and 100 people outdoors.


New outbreak
South Korea reported 288 new cases of the virus on Thursday, the majority of which were in Seoul and the surrounding Gyeonggi province. The outbreak has been linked to the Sarang-jeil Church, which has reported hundreds of positive cases among its members, some 400 of whom have yet to be traced by the authorities.

www.reuters.com 

Tags : #SouthKorea #Phase2humantrial #Greencross #CovidDrug #SarangJeilChurch

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026